PRIMIS has developed stand-alone system searches to help practices identify patients who may be at increased risk of hospitalisation. These patients are not necessarily at an increased risk of contracting COVID-19 but, by keeping them out of hospital, it will help to reduce the current pressure on secondary care services. Equally, as these searches identify patients who are already presenting with long term conditions, these patients may experience complications if they do contract COVID-19. These searches can be downloaded and imported into your GP clinical system FREE OF CHARGE.
If you are looking for information regarding the Coronavirus (COVID-19) shielded patients list, please refer to the NHS Digital website.
The patients identified in these searches may be sub-optimally treated or poorly controlled and would benefit from a structured medication review.
*Factors suggesting greater likelihood of a beneficial response to ICS include those with a history of asthma, blood eosinophil counts based upon exacerbations. Ref: GOLD COPD strategy and NICE NG115
The patients in these searches are potentially at risk of a GI bleed and therefore it can help to reduce demand on secondary care (in terms of emergency admissions) if that risk is mitigated. In all cases consider if there is still a need for the drug that places the patient at risk of a GI bleed (NSAID, anti-coagulant or antiplatelet) before commencement of an ulcer healing drug (PPI). For background information on the evidence behind these searches, please read:
PINCER Evidence Based Summaries document
Click here for both EMIS Web and TPP SystmOne targeted searches
PRIMIS offers a range of clinical quality improvement tools to help practices support their patients with long term condition management. These tools are made available to practices free of charge thanks to national sponsorship. Many of the code groups and associated query logic for the above targeted searches reside within the more comprehensive GRASP-DM and GRASP-COPD tools, which were developed with funding from Boehringer Ingelheim.*
* Boehringer Ingelheim have undertaken a medico legal review of the GRASP tools but PRIMIS retains editorial control and IP rights.
Email us firstname.lastname@example.org
Helpdesk 0115 846 6424
General office and non-helpdesk enquiries 0115 846 6420
Please see Contacting us for further details
Browser does not support script.